Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MMP14 | P50281 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10265072 | 0.86 | MAPT (0.42) | ALDH1A1KDM4EMAPTPOLBRAB9A | |
| SCHEMBL6741043 | 0.86 | MAPT (0.49) | ALDH1A1MAPTHTTPOLBRAB9A | |
| SCHEMBL2791587 | 0.82 | MAPT (0.39) | MAPTSMN1; SMN2POLBRAB9APKM | |
| SCHEMBL23334546 | 0.82 | MAPT (0.42) | MAPTHTTPOLBL3MBTL1RAB9A | |
| SCHEMBL1099100 | 0.79 | RAB9A (0.45) | ALDH1A1MAPTSMN1; SMN2POLBL3MBTL1 | |
| SCHEMBL21640132 | 0.78 | MAPT (0.36) | ALDH1A1MAPTSMN1; SMN2POLBRAB9A | |
| SCHEMBL24525751 | 0.76 | MAPT (0.37) | MAPTHTTSMN1; SMN2POLBRAB9A | |
| SCHEMBL1729465 | 0.76 | MAPT (0.68) | ALDH1A1KDM4EMAPTHTTSMN1; SMN2 | |
| SCHEMBL16230053 | 0.75 | MAPT (0.40) | ALDH1A1MAPTHTTPOLBRAB9A | |
| SCHEMBL30541452 | 0.73 | ALDH1A1 (0.35) | ALDH1A1KDM4EMAPTHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | PLE PATRICK | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | AQP3, AQP1, F12 | ALDH1A1 2449/4885KDM4E 2349/4885MAPT 3649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.